Sophia Liu, Ph.D., currently serves as Core Faculty and Early Independence Fellow at the Ragon Institute of Mass General, MIT, and Harvard since August 2023. Prior to this role, Sophia was a Graduate Research Student at Harvard University from February 2018 to August 2023, where contributions included co-developing a continuous base editor for mammalian cells and measuring RNA transcription dynamics in Dr. Fei Chen's Lab. Additional experience includes working as a Biomedical Data Scientist at nference, analyzing clinical data for drug targets, and serving as a Teaching Assistant at MIT's Educator Program. Earlier roles involved research at the Broad Institute, Genentech, and SQZ Biotech, with a focus on immunology and microfluidic technologies. Sophia holds a Ph.D. in Biophysics from Harvard University and a Bachelor of Sciences in Chemical-Biological Engineering with a minor in Biology from the Massachusetts Institute of Technology.
This person is not in the org chart
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.